DRTS DRTS
Company Profile ↓Company Overview
DRTS (DRTS) is a publicly traded company listed on with a market capitalization of $1.17B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.18.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +339.07% |
| 6 Months: | +81.64% |
| 3 Months: | +79.43% |
| 1 Month: | +3.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 9.31M | 9.65M | 10.73M | 12.60M | 13.31M |
| Operating Income | -9.31M | -9.65M | -10.73M | -12.60M | -13.31M |
| EBITDA | -9.31M | -9.18M | -11.20M | -12.47M | -13.31M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -8.59M | -10.05M | -11.69M | -12.17M | -22.95M |
| Tax Provision | 99.00K | 65.00K | -8.00K | -35.00K | -11.00K |
| Net Income | -8.69M | -10.11M | -11.69M | -12.14M | -22.94M |
| Diluted EPS | -0.12 | - | - | - | -0.26 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 32.14M | 35.68M | 36.04M | 42.29M |
| Operating Income | - | -32.14M | -35.68M | -36.04M | -42.29M |
| EBITDA | - | -32.76M | -27.99M | -30.34M | -40.93M |
| Interest Expense | - | 0 | 75.00K | 303.00K | 347.00K |
| Pretax Income | - | -33.74M | -29.14M | -31.74M | -42.51M |
| Tax Provision | - | 20.00K | 16.00K | 6.00K | 121.00K |
| Net Income | - | -33.76M | -29.16M | -31.75M | -42.63M |
| Diluted EPS | - | -0.53 | -0.42 | -0.45 | -0.53 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 120.15M | 107.39M | 86.20M | 105.65M |
| Current Assets | - | 106.48M | 85.76M | 64.23M | 78.30M |
| Cash & Equivalents | - | 5.84M | 12.66M | 13.72M | 12.20M |
| Inventory | - | - | - | - | - |
| Receivables | - | 313.00K | 344.00K | 332.00K | 336.00K |
| Total Liabilities | - | 14.49M | 22.91M | 23.54M | 28.55M |
| Current Liabilities | - | 4.34M | 7.10M | 8.68M | 10.51M |
| Long Term Debt | - | - | 5.61M | 5.56M | 6.35M |
| Total Debt | - | 5.19M | 13.28M | 12.54M | 13.73M |
| Total Equity | - | 105.66M | 84.47M | 62.67M | 77.10M |
| Shares Outstanding | - | 69.11M | 69.67M | 70.38M | 88.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -23.88M | -17.96M | -19.78M | -26.68M |
| Investing Cash Flow | - | -89.94M | 18.68M | 20.77M | -20.59M |
| Financing Cash Flow | - | 96.91M | 5.30M | 25.00K | 45.77M |
| Capital Expenditure | - | -904.00K | -6.40M | -2.24M | -6.08M |
| Free Cash Flow | - | -24.78M | -24.36M | -22.02M | -32.76M |
| Net Change in Cash | - | -16.91M | 6.02M | 1.01M | -1.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -32.0% | -34.5% | -50.7% | -55.3% |
| ROCE % | - | -27.7% | -35.6% | -46.5% | -44.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DRTS
Alpha Tau Medical (DRTS) Is Down 5.7% After Early-Stop Success In Alpha DaRT Combo Trial
In July 2026, Alpha Tau Medical reported positive podium-presented data from a single-center trial showing that its Alpha DaRT device combined with pembrolizumab achieved a 100% objective response rate and encouraging survival outcomes in e…
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with lo…
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson team, led by Dr. Sam…
New Strong Sell Stocks for July 7th
AMPX, DRTS and BELFB have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2026.
New Strong Sell Stocks for July 2nd
DRTS, CANG and LAZ have been added to the Zacks Rank #5 (Strong Sell) List on July 2, 2026.
Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform
Alpha Tau Medical recently reported that its Alpha DaRT technology was used to safely treat a recurrent glioblastoma patient in Israel, marking the first intracranial application of its brain-specific delivery system outside the United Stat…
DRTS — Frequently Asked Questions
What is the current share price of DRTS?
As of 2026-08-05 17:25 PDT, DRTS trades at $13.26 on NASDAQ/NYSE. Its 52-week range is $3.02 to $13.58.
What is the market capitalisation of DRTS?
DRTS has a market capitalisation of $1.17B on NASDAQ/NYSE.
What is the P/E ratio of DRTS?
DRTS trades at a trailing price-to-earnings (P/E) ratio of -25.02. Its price-to-book (P/B) ratio is 15.14.
What is the return on equity (ROE) of DRTS?
DRTS has a return on equity (ROE) of -55.29%. Its return on capital employed (ROCE) is -44.45%.
Is DRTS a good stock to buy?
This page provides a data-driven analysis of DRTS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.